AdamisPharmaceuticals Corp. (ADMP) stock prices were up by a significant 17.84% shortly after market trading commenced on June 7th, 2021, bringing the price per share up to USD$1.1784 early on in the trading day.
The company announced on June 7th, 2021 that the National Institute of Health (NIH) had identified the company’s proprietary experimental drug, TEMPOL, as a potentially effective antiviral for the coronavirus pandemic. The results of a study conducted by NIH researchers of cell cultures, Tempol indicated being effective in the limited of SARS-CoV-2 infection by impairing the activity of a viral enzyme known as RNA replicase.
Treatment for Covid-19
The NIH study also suggested that the treatment’s doses used in the antiviral studies could likely be achieved in tissues that are the primary targets for the virus. The treatment’s efficacy was discovered via the assessment of the question of how the coronavirus utilizes its RNA replicase, which is an enzyme that enables SARS-CoV-2 to replicate its genome and make copies of itself when inside a cell.
The study rectified previous erroneous studies that mistakenly concluded that iron-sulfur cluster binding sites were zinc-binding sites. NIH researchers who tested the requirement of iron-sulfur clusters for structural support in RNA replicase and the enzyme’s nsp12 sub-unit. Findings indicated that two iron-sulfur clusters were needed for the SARS-CoV-2 RNA replicase to function optimally.
Efficacy of TEMPOL
In light of these findings by NIH researchers, the discovery that TEMPOL can degrade iron-sulfur clusters has been ground-breaking in the push for the proliferation of the treatment to address the global pandemic. Additional studies are intended to be carried out to further explore the efficacy and scope of TEMPOL as a treatment for Covid-19, with its evaluation in a clinical study priming it for its eventual commercialization.
TEMPOL has hitherto also shown anti-inflammatory and anti-oxidant capabilities in conjunction to its potential antiviral treatment for Covid-19. With the studies being conducted at the Galveston National Lab, hamsters were infected with the coronavirus and then administered with a treatment of TEMPOL. The animals that were administered TEMPOL showed promising signs of decreased lung inflammation, as compared to the control group.
Future Outlook for ADMP
With the world hurtling towards universal immunizations, ADMP is poised to capitalize on the opportunity it has found in the burgeoning market. The promising research paves the way for future trials that will push TEMPOL through to commercialization. Current and potential investors are hopeful that the company will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.